Condition: Bile Duct Cancer · Cholangiocarcinoma · Cholangiocarcinoma Non-resectable · Sponsor: Beth Israel Deaconess Medical Center
This trial is designed to study a combination of interventions (chemotherapy, immunotherapy, and radiation) as a potential new treatment for bile duct cancer that cannot be removed with surgery. The specific names of the interventions that will be used are: * Y-90 (a type of radiation microsphere bead) * Durvalumab (a type of immunotherapy) * Gemcitabine (a type of chemotherapy) * Cisplatin (a type of chemotherapy)
This description comes directly from the study's public registry record.
Andrea Bullock, MD, MPH · 617-667-2100 · abullock@bidmc.harvard.edu
Selma Sinanovic, BS · 617-667-2100 · ssinanov@bidmc.harvard.edu
Always discuss trial participation with your own doctor first.
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05655949